Mizoribine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mizoribine
Accession Number
DB12617
Type
Small Molecule
Groups
Investigational
Description

Mizoribine has been investigated for the treatment of Rheumatoid Arthritis.

Structure
Thumb
Synonyms
  • BREDININ
External IDs
Not Available
Product Ingredients
Not Available
Approved Prescription Products
Not Available
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
4JR41A10VP
CAS number
50924-49-7
Weight
Average: 259.216
Monoisotopic: 259.080435163
Chemical Formula
C9H13N3O6
InChI Key
HZQDCMWJEBCWBR-UUOKFMHZSA-N
InChI
InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1
IUPAC Name
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1H-imidazole-4-carboxamide
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 5-androstenedione.Experimental, Illicit
AbciximabMizoribine may increase the anticoagulant activities of Abciximab.Approved
AcebutololMizoribine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Mizoribine.Approved
AcenocoumarolMizoribine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Mizoribine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mizoribine.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mizoribine.Approved, Vet Approved
AclarubicinMizoribine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mizoribine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alendronic acid.Approved
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
AliskirenMizoribine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololMizoribine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mizoribine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Amcinonide.Approved
AmikacinMizoribine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMizoribine may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinMizoribine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMizoribine may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Mizoribine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Mizoribine is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Mizoribine.Investigational
annamycinMizoribine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Mizoribine.Approved
Antithrombin III humanMizoribine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanMizoribine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Mizoribine.Investigational
ApramycinMizoribine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Mizoribine.Approved, Investigational
ArbekacinMizoribine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinMizoribine may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanMizoribine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMizoribine may decrease the antihypertensive activities of Arotinolol.Approved
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Mizoribine.Approved
AtenololMizoribine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Mizoribine.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mizoribine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mizoribine.Approved
BalsalazideMizoribine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Mizoribine.Investigational
BecaplerminMizoribine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMizoribine may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mizoribine.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mizoribine.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mizoribine.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mizoribine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Betamethasone.Approved, Vet Approved
BetaxololMizoribine may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Mizoribine.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Mizoribine.Approved, Investigational
BevantololMizoribine may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mizoribine.Approved, Investigational
BisoprololMizoribine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMizoribine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Mizoribine.Investigational
BopindololMizoribine may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mizoribine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Mizoribine.Investigational
BucindololMizoribine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Budesonide.Approved
BufuralolMizoribine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideMizoribine may decrease the diuretic activities of Bumetanide.Approved
BupranololMizoribine may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mizoribine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mizoribine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mizoribine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Mizoribine.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mizoribine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Mizoribine.Approved, Vet Approved, Withdrawn
CarteololMizoribine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMizoribine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Mizoribine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Celecoxib.Approved, Investigational
CeliprololMizoribine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMizoribine may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mizoribine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mizoribine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mizoribine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Mizoribine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mizoribine.Approved
CinoxacinMizoribine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinMizoribine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidMizoribine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Mizoribine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mizoribine.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Mizoribine.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mizoribine.Approved, Investigational
CyclosporineMizoribine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Mizoribine.Investigational
Dabigatran etexilateMizoribine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMizoribine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMizoribine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapsoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dapsone.Approved, Investigational
DarexabanMizoribine may increase the anticoagulant activities of Ym150.Investigational
DaunorubicinMizoribine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Mizoribine is combined with Deferasirox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mizoribine.Approved
DesirudinMizoribine may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mizoribine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mizoribine.Approved
DextranMizoribine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Mizoribine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Mizoribine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Mizoribine may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mizoribine.Approved, Vet Approved
DicoumarolMizoribine may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mizoribine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mizoribine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mizoribine.Approved
DihydrostreptomycinMizoribine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mizoribine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mizoribine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mizoribine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mizoribine.Approved, Investigational
DoxorubicinMizoribine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneMizoribine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Mizoribine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Mizoribine.Investigational
E-6201The risk or severity of adverse effects can be increased when E6201 is combined with Mizoribine.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Mizoribine.Investigational
Edetic AcidMizoribine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMizoribine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mizoribine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mizoribine.Approved
EnoxacinMizoribine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinMizoribine may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Mizoribine.Approved
EpirubicinMizoribine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMizoribine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mizoribine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mizoribine.Approved
EquileninThe risk or severity of adverse effects can be increased when Mizoribine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Equilin.Approved
EsmololMizoribine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Estrone sulfate.Approved
Etacrynic acidMizoribine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mizoribine.Approved, Investigational
Ethyl biscoumacetateMizoribine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Mizoribine.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Mizoribine.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Mizoribine.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Mizoribine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mizoribine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Mizoribine.Vet Approved
FingolimodMizoribine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinMizoribine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mizoribine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fludrocortisone.Approved
FluindioneMizoribine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMizoribine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Mizoribine.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluorometholone.Approved
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Mizoribine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Mizoribine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mizoribine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mizoribine.Approved, Nutraceutical, Vet Approved
FondaparinuxMizoribine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMizoribine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mizoribine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mizoribine.Approved
FramycetinMizoribine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMizoribine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Mizoribine is combined with G17DT.Investigational
GabexateMizoribine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMizoribine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMizoribine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mizoribine.Approved, Withdrawn
GemifloxacinMizoribine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMizoribine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMizoribine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMizoribine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The risk or severity of adverse effects can be increased when Mizoribine is combined with GI-5005.Investigational
GrepafloxacinMizoribine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mizoribine is combined with HE3286.Investigational
HeparinMizoribine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Mizoribine.Investigational
HydralazineMizoribine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mizoribine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mizoribine.Approved
Hygromycin BMizoribine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Mizoribine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Mizoribine.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Mizoribine.Approved
IdarubicinMizoribine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxMizoribine may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mizoribine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mizoribine.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mizoribine.Approved
IndenololMizoribine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mizoribine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Mizoribine.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Mizoribine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Mizoribine is combined with INGN 225.Investigational
INNO-206Mizoribine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mizoribine.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Mizoribine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Mizoribine is combined with Istaroxime.Investigational
KanamycinMizoribine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Mizoribine.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mizoribine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mizoribine.Approved
LabetalolMizoribine may decrease the antihypertensive activities of Labetalol.Approved
LandiololMizoribine may decrease the antihypertensive activities of Aop200704.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mizoribine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Leflunomide.Approved, Investigational
LepirudinMizoribine may increase the anticoagulant activities of Lepirudin.Approved
LevobunololMizoribine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMizoribine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mizoribine.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mizoribine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mizoribine.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Mizoribine.Approved
LomefloxacinMizoribine may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Mizoribine.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mizoribine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Mizoribine.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mizoribine.Approved, Investigational
LumefantrineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Mizoribine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mizoribine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mizoribine.Approved
ME-609The risk or severity of adverse effects can be increased when Mizoribine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mizoribine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mizoribine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mizoribine.Approved, Vet Approved
MesalazineMizoribine may increase the nephrotoxic activities of Mesalazine.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Mizoribine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Mizoribine.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mizoribine.Approved
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mizoribine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mizoribine.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Mizoribine.Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMizoribine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mizoribine.Approved
MetoprololMizoribine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMizoribine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mizoribine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mizoribine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Mometasone.Approved, Vet Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Mizoribine.Approved, Withdrawn
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mizoribine.Approved
MoxifloxacinMizoribine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mizoribine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mizoribine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Nabumetone.Approved
NadololMizoribine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMizoribine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMizoribine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mizoribine.Approved
Nalidixic AcidMizoribine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Mizoribine.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Mizoribine is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Mizoribine is combined with NCX 1022.Investigational
NeamineMizoribine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinMizoribine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMizoribine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Mizoribine.Approved
NetilmicinMizoribine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mizoribine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mizoribine.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mizoribine.Investigational
NorfloxacinMizoribine may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinMizoribine may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Mizoribine.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mizoribine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mizoribine.Approved
OlsalazineMizoribine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mizoribine.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Mizoribine.Vet Approved
OtamixabanMizoribine may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Mizoribine.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mizoribine.Approved
OxprenololMizoribine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mizoribine.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mizoribine.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Parecoxib.Approved
ParomomycinMizoribine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinMizoribine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMizoribine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMizoribine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateMizoribine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Mizoribine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mizoribine.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Mizoribine.Approved
PhenindioneMizoribine may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonMizoribine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mizoribine.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mizoribine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mizoribine.Approved, Investigational
PindololMizoribine may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinMizoribine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMizoribine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Mizoribine.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mizoribine.Approved, Investigational
PlicamycinMizoribine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mizoribine.Approved
PractololMizoribine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mizoribine.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Mizoribine is combined with dehydroepiandrosterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Mizoribine can be increased when it is combined with Probenecid.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Mizoribine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Mizoribine.Approved
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Mizoribine.Vet Approved
PropranololMizoribine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mizoribine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mizoribine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Mizoribine.Vet Approved
Protein CMizoribine may increase the anticoagulant activities of Protein C.Approved
Protein S humanMizoribine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMizoribine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMizoribine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Mizoribine.Investigational
PuromycinMizoribine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mizoribine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mizoribine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Mizoribine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mizoribine.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mizoribine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mizoribine.Experimental, Investigational
ReviparinMizoribine may increase the anticoagulant activities of Reviparin.Approved
RibostamycinMizoribine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Mizoribine is combined with CDX-110.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Risedronate.Approved, Investigational
RivaroxabanMizoribine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rofecoxib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Mizoribine.Approved
RosoxacinMizoribine may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mizoribine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Mizoribine.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mizoribine.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Mizoribine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mizoribine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mizoribine.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mizoribine.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mizoribine.Approved
SisomicinMizoribine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolMizoribine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMizoribine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMizoribine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinMizoribine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mizoribine.Approved
SpironolactoneMizoribine may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Mizoribine is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Mizoribine.Investigational
StreptomycinMizoribine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMizoribine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineMizoribine may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mizoribine.Approved
SulodexideMizoribine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mizoribine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Mizoribine.Approved, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Mizoribine.Approved, Investigational
TacrolimusMizoribine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mizoribine.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mizoribine.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mizoribine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mizoribine.Approved, Investigational
TemafloxacinMizoribine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mizoribine.Experimental, Investigational
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mizoribine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Mizoribine.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Mizoribine.Approved
TG4010The risk or severity of adverse effects can be increased when Mizoribine is combined with TG4010.Investigational
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Mizoribine.Withdrawn
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mizoribine.Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Mizoribine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tiludronate.Approved, Vet Approved
TimololMizoribine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Mizoribine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tixocortol.Approved
TobramycinMizoribine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibMizoribine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mizoribine.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mizoribine.Approved
TorasemideMizoribine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mizoribine.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Mizoribine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mizoribine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mizoribine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mizoribine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMizoribine may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mizoribine.Approved, Vet Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Mizoribine.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
TrovafloxacinMizoribine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mizoribine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Mizoribine is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinMizoribine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mizoribine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mizoribine.Approved
WarfarinMizoribine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMizoribine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mizoribine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mizoribine.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mizoribine.Withdrawn
ZorubicinMizoribine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB41934
ChemSpider
94571
BindingDB
68669
ChEBI
31858
ChEMBL
CHEMBL245019
HET
MZR
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentRheumatoid Arthritis1
3RecruitingTreatmentGlomerulonephritis minimal lesion1
3RecruitingTreatmentNephritis, Lupus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility36.1 mg/mLALOGPS
logP-2.3ALOGPS
logP-2ChemAxon
logS-0.86ALOGPS
pKa (Strongest Acidic)8.19ChemAxon
pKa (Strongest Basic)2.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area151.06 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity55.55 m3·mol-1ChemAxon
Polarizability23.58 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as 1-ribosyl-imidazolecarboxamides. These are organic compounds containing the imidazole ring linked to a ribose ring through a 1-2 bond.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Nucleosides, nucleotides, and analogues
Sub Class
Imidazole ribonucleosides and ribonucleotides
Direct Parent
1-ribosyl-imidazolecarboxamides
Alternative Parents
Glycosylamines / Pentoses / 2-heteroaryl carboxamides / Carbonylimidazoles / N-substituted imidazoles / Vinylogous amides / Vinylogous acids / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols
show 8 more
Substituents
1-ribosyl-imidazolecarboxamide / Glycosyl compound / N-glycosyl compound / Pentose monosaccharide / 2-heteroaryl carboxamide / Imidazole-4-carbonyl group / N-substituted imidazole / Monosaccharide / Azole / Tetrahydrofuran
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Drug created on October 20, 2016 17:14 / Updated on September 01, 2017 12:23